ArticlePloS one2025
MAFLD in Egyptian non-dialysis CKD Patients: Frequency, fibrosis severity, and risk factors.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in non-dialysis chronic kidney disease (CKD) patients remains underexplored, particularly in high-risk populations such as Egyptians with high rates of metabolic disorders.
aimsThis study aimed to determine the frequency of MAFLD in Egyptian non-dialysis CKD patients, assess liver fibrosis severity, and identify associated metabolic risk factors.
methodsA cross-sectional study of 108 CKD patients was conducted, with participants stratified into MAFLD (n = 64) and non-MAFLD (n = 44) groups. Diagnostic criteria for MAFLD included hepatic steatosis (ultrasonography) and metabolic risk factors. Non-invasive fibrosis scores (NAFLD score, FIB-4 index, APRI score) and shear wave elastography were used to evaluate liver fibrosis.
resultsMAFLD prevalence was 59.25%. MAFLD patients exhibited significant associations with older age (56 ± 17.1 vs. 43 ± 17.1 years, p < 0.001), higher BMI (34.5 ± 6.2 vs. 27.2 ± 5.7 kg/m2, p < 0.001), diabetes (48.4% vs. 4.5%, p < 0.001), hypertension (68.7% vs. 22.7%, p < 0.001), and insulin resistance (HOMA-IR: 3.5 ± 3.6 vs. 1.45 ± 1.03, p < 0.001). MAFLD patients also had lower eGFR (40.5 ± 28.0 vs. 58.9 ± 39.9 mL/min/1.73 m2, p = 0.017) and higher liver stiffness (7.6 ± 1.8 vs. 6.9 ± 1.7 kPa, p = 0.047), with advanced fibrosis more prevalent in later CKD stages..
conclusionMAFLD is highly prevalent among non-dialysis CKD patients, driven by shared metabolic abnormalities and CKD severity. These findings highlight the bidirectional relationship between MAFLD and CKD, emphasizing the need for integrated screening and management strategies to mitigate progression risks in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.